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DB289 is the first oral drug shown in clinical trials to have 
efficacy in treating African trypanosomiasis (African sleeping 
sickness). Mild liver toxicity was noted but was not treatment 
limiting. However, development of DB289 was terminated when 
several treated subjects developed severe kidney injury, a liability 
not predicted from preclinical testing. We tested the hypothesis 
that the kidney safety liability of DB289 would be detected in a 
mouse diversity panel (MDP) comprised of 34 genetically diverse 
inbred mouse strains. MDP mice received 10 days of oral treat-
ment with DB289 or vehicle and classical renal biomarkers blood 
urea nitrogen (BUN) and serum creatinine (sCr), as well as urine 
biomarkers of kidney injury were measured. While BUN and 
sCr remained within reference ranges, marked elevations were 
observed for kidney injury molecule-1 (KIM-1) in the urine of sen-
sitive mouse strains. KIM-1 elevations were not always coincident 
with elevations in alanine aminotransferase (ALT), suggesting 
that renal injury was not linked to hepatic injury. Genome-wide 
association analyses of KIM-1 elevations indicated that genes par-
ticipating in cholesterol and lipid biosynthesis and transport, oxi-
dative stress, and cytokine release may play a role in DB289 renal 
injury. Taken together, the data resulting from this study highlight 
the utility of using an MDP to predict clinically relevant toxicities, 
to identify relevant toxicity biomarkers that may translate into the 
clinic, and to identify potential mechanisms underlying toxicities. 
In addition, the sensitive mouse strains identified in this study may 
be useful in screening next-in-class compounds for renal injury.
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Human African trypanosomiasis (HAT), also known as 
sleeping sickness, is a vector-borne parasitic disease caused 
by Trypanosoma brucei subspecies transmitted to humans by 
the bite of infected tsetse flies. The disease is primarily found 
in areas indigenous to the tsetse fly, particularly rural areas of 
sub-Saharan Africa. Despite improvements in regional HAT 
control, the disease remains prevalent and new treatments are 
needed. It has been recently estimated that there are slightly 
fewer than 10,000 new cases reported each year; as a result, 
the World Health Organization has identified HAT as a core 
neglected tropical disease (Molyneux and Malecela, 2011). 
If left untreated, HAT progresses to a second stage involving 
the central nervous system, which can be fatal. There are few 
therapeutic agents available to treat the disease and these have 
several drawbacks, including the need for parenteral admin-
istration, and a high incidence of adverse events that can be 
severe or fatal. In addition, resistance to available drugs is a 
growing concern (Delespaux and de Koning, 2007).
To address this unmet need, the Consortium for Parasitic 
Drug Development (CPDD) developed the first oral drug 
to treat HAT, DB289 (pafuramidine maleate; 2,5-bis(4-
amidinophenyl)-furan-bis-O-methylamidoxime). DB289 is a 
diamidine prodrug (Thuita et al., 2008; Yeramian et al., 2005) 
that is converted to the active metabolite DB75 (furamidine; 
2,5-bis(4-aminophenyl)-furan), which exhibits a broad 
spectrum of antiparasitic activity for Trypanosoma subspecies. 
DB289 efficacy was demonstrated in phase II and phase 
III trials conducted in the Democratic Republic of Congo, 
Angola, and Sudan. The major safety concern noted in these 
treatment trials was a 7% incidence of liver injury; however, the 
incidence of this adverse event was substantially less than in the 
comparator group treated with the usual first line HAT therapy, 
pentamidine (77%).
Despite the promising results of this clinical trial, further 
development of DB289 was abruptly terminated due to an 
expanded safety trial conducted in South Africa. In this trial, 100 
healthy adult volunteers were treated with 100 mg DB289 b.i.d. 
for 14 days. As expected, generally mild and reversible liver 
injury was observed. However, 6 of 100 subjects experienced 
delayed renal insufficiency, and 1 subject required extended 
dialysis. Whereas preclinical testing in rats and monkeys had 
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demonstrated liver injury as a dose-limiting event, these stud-
ies had not suggested the potential for DB289 to cause kidney 
injury. Identification of an animal model for DB289 kidney 
injury was important because similar aza analogs have shown 
promise in ability to treat second-stage HAT and are under con-
sideration for clinical trials.
Since kidney injury due to DB289 had only been reported 
in the South African population, we hypothesized that genetic 
variation may underlie susceptibility to this serious adverse 
event. We reasoned that the introduction of genetic diversity 
to preclinical screening might have detected the kidney safety 
liability of DB289. The Mouse Diversity Panel (MDP) is a com-
mercially available panel of well-characterized inbred mouse 
strains that have a genetic diversity comparable to a heteroge-
neous human population (McClurg et al., 2007). An advantage 
of the MDP is that because the genetics of each mouse strain 
are extensively characterized, it provides the means for detect-
ing genes that contribute to a variable response, such as toxic 
response. This approach has previously been utilized to iden-
tify genetic variants that contribute to susceptibility to toxicity 
due to acetaminophen (Harrill et al., 2009a,b; Liu et al., 2010) 
and trichloroethylene (Bradford et al., 2011) exposures. In the 
case of acetaminophen-induced liver toxicity, the MDP identi-
fied that variation in the gene for CD44 was associated with an 
increased risk of toxicity in mice and this association was sub-
sequently validated in clinical cohorts (Harrill et al., 2009b). In 
this study, it was hypothesized that the MDP pharmacogenetic 
approach would detect the kidney injury potential DB289 and 
would additionally provide mechanistic insight into the toxicity.
MATERIALS AND METHODS
Drugs and internal standards. DB289, DB75, and deuterated standards 
were acquired from the CPDD and were synthesized according to previously 
described methods (Boykin et al., 1995; Saulter et al., 2005) in the laboratories 
of Dr David Boykin (Georgia State University).
Animals. Male and female mice aged 6–8 weeks were obtained from The 
Jackson Laboratory or Charles River (CD-1) and housed in the Laboratory 
Animal Resources and Technical Support Facility at The Hamner Institutes. 
Mice utilized in this study from the Jackson Laboratory comprised 34 inbred 
strains that are priority strains for the Mouse Phenome Project (Bogue and 
Grubb, 2004). Mice were allowed to acclimate to the facility for 2 weeks prior 
to dosing; during this time, animals were randomized to treatment groups by 
body weight using the Instem Provantis system. Animals were given water ad 
libitum throughout the study and were fed NIH-07 wafer feed except for the 
time period 18 h prior to necropsy. Animals were maintained on a 12-h light-
dark cycle. Care of mice followed institutional guidelines under a protocol 
approved by the Institutional Animal Care and Use Committee.
DB289 administration. DB289 dosage selection was based on a pilot 
study in which CD-1 male and female mice were administered 0, 75, 125, or 
250 μmol/kg of DB289 daily for 2, 4, or 14 days (i.e., with five mice per group); 
due to significant morbidity and mortality caused by higher doses, 75 μmol/
kg was utilized for the inbred strain panel study in female mice. An initial 
evaluation of this dose in two inbred mouse strains, BALB/cByJ and C3H/HeJ, 
demonstrated that DB289 caused a marked decrease in body weight in sensitive 
mice; therefore, a 10-day treatment regimen was selected. Mice from 34 inbred 
strains were randomized into treatment groups and dosed intragastrically with 
75 μmol/kg DB289 (N = 5 per strain) or vehicle (N = 5 per strain, 0.5% methyl 
2-hydroxyethyl cellulose; Sigma-Aldrich) once daily for 10 days with a dosing 
volume of 10 ml/kg for all doses. Dosing was performed at the same time of 
day throughout the study to avoid diurnal variability (Boorman et al., 2005). 
Animals were fasted 18 h prior to necropsy.
Sample collection. Urine was collected in chilled containers for 18 h over-
night between study days 3–4, 7–8, and 10–11 using mouse metabolic cages 
(Hatteras Instruments, Inc., Cary, NC). Total urine volume was measured. On 
day 11, animals were euthanized by CO
2
 asphyxia and blood was collected via 
cardiac puncture. The livers and kidneys were quickly excised and sections of 
the left liver lobe and left kidney were placed in 10% phosphate-buffered for-
malin for histological analyses. The remaining tissue was snap-frozen in liquid 
nitrogen and stored at −80°C. Mice of strain P/J underwent necropsy 24 h ahead 
of schedule, on day 10, due to morbidity associated with treatment.
Clinical Chemistry
Samples were assayed for serum biomarkers by standard enzymatic proce-
dures using a SpectraMax microtiter plate reader (Molecular Devices, LLC). 
Blood urea nitrogen (BUN) was assayed using the MaxDiscovery Blood Urea 
Nitrogen Enzymatic Kit (Bioo Scientific Corporation) using the manufacturer’s 
recommendations. The Quantichrom Creatinine Assay Kit (BioAssay Systems) 
was utilized to measure creatinine in the serum (sCr) using the manufacturer’s 
protocol.
Kidney Injury Molecule-1 Measurements
Biomarkers that were assayed in mouse pilot studies included kidney 
injury molecule-1 (KIM-1; proximal tubule injury; Uscn Life Science, Inc.) 
β2-microglobulin (glomerular injury; Uscn Life Science, Inc.), Lipocalin-2/
NGAL (renal epithelial injury; R&D Systems, Inc.), tissue inhibitor of metallo-
proteinases 1 (TIMP-1; R&D Systems, Inc.), and cystatin C (glomerular injury; 
BioVendor, LLC). KIM-1 was quantified in urine collected overnight prior to 
necropsy using the ELISA Kit for KIM-1 (Uscn Life Science, Inc.) as detailed 
by the manufacturer. Briefly, samples and standards were added to a micro-
titer plate precoated with biotin-conjugated polyclonal antibody preparation 
specific to KIM-1. Avidin conjugated with horseradish peroxidase was then 
incubated in each well prior to the addition of a substrate solution that elicited 
a colorimetric change. The reaction was halted upon addition of sulfuric acid 
solution, and KIM-1 was quantified spectrophotometrically at a wavelength of 
450 nm. Sample values were calculated using a standard curve and normalized 
to the urine volume collected over the 18-h collection period.
Measurement of DB75 Tissue Concentrations
Kidney specimens were processed for quantification of DB75, the active 
metabolite of DB289, by high-performance liquid chromatography/triple 
quadrupole mass spectrometry (HPLC/MS-MS) using a previously published 
method (Wang et  al., 2010)  with modifications. Briefly, specimens were 
homogenized with two volumes of HPLC-grade water (1 g of wet tissue was 
considered equivalent to 1 ml in volume) using a sonic dismembrator (Model 
120; Fisher Scientific Co.). Homogenates obtained from DB289-treated 
animals were diluted 1:10 (vol/vol) with blank rat kidney homogenate. DB75 
was extracted by mixing homogenates (25  μl) with 200  μl of 7:1 (vol/vol) 
methanol:water containing 0.1% (vol/vol) trifluoroacetic acid and 100μM 
internal standard (DB75-d
8
). After centrifugation and evaporation of the 
resulting supernatants, the remaining pellet was reconstituted with 100  μl 
of 15% (vol/vol) methanol containing 0.1% (vol/vol) trifluoroacetic acid. 
DB75 quantification employed an HPLC-MS/MS system consisting of two 
Shimadzu solvent delivery pumps, a Valco (Valco Instruments Co., Inc.) 
switching valve, and a thermostated (6°C) LEAP HTC autosampler (LEAP 
Technologies) connected to an Applied Biosystems API 4000 triple quadrupole 
mass spectrometer equipped with a heated nebulizer (APCI) ionization source. 
Reverse-phase gradient chromatography, conducted at a flow rate of 0.75 ml/
min, was used to elute DB75 and DB75-d
8
 from an Aquasil C
18
 HPLC column 
(50 × 2.1 mm, 5 µm; Thermo Fisher Scientific, Waltham, MA) following a 4-µl 
injection of reconstituted pellet. Mobile phase (A) consisted of HPLC-grade 
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water with 35mM formic acid and 15mM ammonium acetate; (B) consisted 
of 80:20 (vol/vol) acetonitrile:water with 35mM formic acid and 15mM 
ammonium acetate. The initial gradient condition was 100% A, which was held 
for 0.5 min. From 0.5 to 4 min, B increased linearly to 90%. The eluent was 
directed to waste for the first 0.6 min of each injection, then directed to the mass 
spectrometer. At 4 min, the eluent was redirected to waste, and the column was 
washed with 90% B for 1 min. The system was re-equilibrated for 1 min with 
100% A.  Total run time was 6 min/injection. Automated sample acquisition 
and data analysis were accomplished using Analyst software (version 1.4.1; 
Applied Biosystems). DB75 and DB75-d
8
 were analyzed in positive ion mode 
using the following transitions preset in multiple reaction monitoring scans: 
305.1  → 288.1 (DB75) and 313.2  → 296.2 (DB75-d
8
). Duplicate 11-point 
calibration curves for DB75 (100–250,000nM), prepared in blank mouse 
kidney homogenate, were constructed using the peak area ratio of DB75 to 
DB75-d
8
 and fit with a quadratic equation using 1/x weighting. Quality controls 
and dilution controls (1:10 in blank rat kidney homogenate) were prepared in 
triplicate. The lower limit of quantification (LLQ) was 100nM. Accuracy and 
precision were at least 85 and 6%, respectively.
Histology
Formalin-fixed kidney and liver specimens were embedded in paraffin, and 
5-µm sections cut in duplicate were applied to each slide. Sections were stained 
with hematoxylin and eosin. Liver and kidney tissue from the CD-1, BALB/cByJ, 
and C3H/HeJ pilot studies were assessed by light microscopy by a pathologist 
blinded to treatment assignment (Experimental Pathology Laboratories, Inc.).
Quantitative Trait Locus Mapping
Genome-wide association (GWA) mapping was performed as described 
elsewhere using efficient mixed-model association (EMMA; Kang et  al., 
2008). In this approach, a mixed model was used to incorporate pairwise gen-
etic relatedness between every pair of mouse strains in the statistical model 
directly. Thus, the number of false positives due to the inherent genetic related-
ness of strains is reduced, while simultaneously increasing the power to detect 
causative QTL. Briefly, GWA was performed in R (http://cran.r-project.org) 
using a 260,733 single-nucleotide polymorphism (SNP) dataset and the fold 
change (DB289/vehicle) for urinary KIM-1 or for serum ALT for each strain. 
Eight strains (NOD/ShiLtJ, NZW/LacJ, SWR/J, C57BR/cdJ, C58/J, P/J, SEA/
GnJ, and I/LnJ) had KIM-1 values below the limit of quantitation or mortal-
ity that prevented sample collection, and were therefore excluded from asso-
ciation analysis. −Log P values were plotted across the mouse genome using 
the RGenetics package in Galaxy (http://main.g2.bx.psu.edu/). Genomic inter-
vals with association scores greater than the Bonferroni correction threshold 
were considered significant (−log
10
 P ≥ 6.84). Genes within significant inter-
vals were identified with Ensembl and the UCSC Genome Browser using 
NCBI mouse genome build 37 (http://www.ensembl.org; http://genome.ucsc.
edu). Network analysis was performed using the pathway explorer function 
in Ingenuity Pathway Analysis (Ingenuity Systems, Redwood City, CA). The 
genetic network was recreated using Microsoft PowerPoint for visual clarity.
Statistical Methods
Phenotypic values were expressed as the mean ± standard error of the 
mean. Differences between vehicle and DB289-treated mice within a strain 
were determined via a two-tailed Student’s t-test. Correlation between study 
endpoints was assessed by linear regression analysis using GraphPad Prism 
(GraphPad Software, Inc.). Statistical outcomes were considered significant 
when the p-value was < 0.05.
RESULTS
Determination of Optimal DB289 Dosing Conditions
To determine the optimal dose for the MDP study, a dose 
range-finding experiment was conducted in CD-1 mice. The 
highest doses of DB289 were not well tolerated during the 14-day 
exposure with three (one male and two females) animals at the 
125 μmol/kg dose level and nine animals (five males and four 
females) at the 250 μmol/kg found dead or euthanized early due 
to moribundity. Dose-dependent hepatocellular necrosis was evi-
dent in the liver of CD-1 mice, but was minimal at the 75 μmol/
kg dose. Severe liver injury observed histologically, character-
ized by centrilobular necrosis, inflammation, hemorrhage, and 
fibrosis, was suspected by the study pathologist to have plausibly 
contributed to the observed morbidity and mortality.
Minimal to mild degeneration and necrosis was observed in 
the proximal tubule epithelia of the kidney in the female CD-1 
mice treated at all three dose levels (Supplemental tables 1 
and 2). This pathology was also observed in males but only 
at the 125 and 250 μmol/kg dose levels. The observed kidney 
pathology was not associated with increases in sCr or BUN 
(Supplemental table 1).
Due to the observed kidney lesions, modest liver injury, 
and lack of morbidity in CD-1 mice at the lowest dose level, 
exposure to 75  μmol/kg DB289 for 14  days in female mice 
was initially selected as the experimental design for the inbred 
strain study. However, due to weight loss observed in BALB/
cByJ mice treated with DB289 in a subsequent study, the dos-
ing duration was shortened to 10 days.
Consistent with observations in female CD-1 mice, sCr and 
BUN were not elevated in female BALB/cByJ or C3H/HeJ 
mice tested in the subsequent tolerability study. Urine was 
assayed for KIM-1, β2-microglobulin, TIMP-1, and cystatin 
C to determine the optimal kidney injury biomarker to assay. 
KIM-1 exhibited the largest elevations and dynamic range 
due to DB289 treatment, consistent with the restriction of the 
observed histological lesions to the proximal tubule in CD-1 
mice (Supplemental table 2).
Effects of DB289 on Animal Health Outcomes in the MDP
DB289 was well tolerated in the majority of mouse strains 
tested. However, all DB289-treated animals of strains C58/J, 
MA/MyJ, NOR/LtJ, NZW/LacJ, P/J, PL/J, and SM/J received 
supportive care due to minor dehydration and weight loss 
associated with drug treatment. Supportive care consisted of 
subcutaneous injections of saline and the addition of HydroGel 
(Clear H
2
O) to the diet. One C58/J animal was euthanized early 
and all five P/J mice treated with DB289 underwent necropsy 
24 h ahead of schedule due to drug-associated morbidity.
Kidney weights (relative to the body weight) were affected 
by DB289 treatment in 10/34 (29%) strains (Fig. 1A). There 
was a significant decrease in strains C3H/HeJ, BTBR T + tf/J, 
BUB/BnJ, C57BR/cdJ, C58/J, MRL/MpJ, I/LnJ, and WSB/EiJ 
(P < 0.05). A significant increase in kidney to body weight in 
strains C57BLKS/J and MA/MyJ was observed.
DB289 exposure resulted in decreased liver weight with 
respect to the body weight in the majority (24/34; 71%) of 
strains tested (Fig. 1B). More than half (55%) of the mouse 
strains exhibited a significant decrease in body weight 
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between the first day and last day of dosing with DB289 (data 
not shown). However, of the eight strains for which there was 
a significant decrease in the kidney:body weight ratio, only 
two exhibited a treatment-related decrease in body weight 
(C58/J and MRL/MpJ). There were seven mouse strains 
for which a decrease in the liver:body weight ratio was not 
accompanied by a significant decrease in body weight dur-
ing the dosing interval; these strains included A/J, BTBR + 
tf/J, BUB/BnJ, C3H/HeJ, C57BR/cdJ, DBA/2J, and FVB/NJ. 
Taken together, these data suggest that in selected strains a 
decrease in liver or kidney weight was unrelated to changes 
in body weight.
Liver Injury in Mice Following DB289 Exposure
To determine the extent to which the liver was affected across 
the MDP following DB289 exposure, alanine aminotransferase 
(ALT) was quantified in serum collected during necropsy. The 
majority (29/34 or 85%) of strains tested exhibited a significant 
increase in ALT levels as a result of DB289 treatment; however, 
response varied across strains. ALT fold increases from base-
line ranged from none in strain C58/J (0.1 ± 1.1 fold increase) 
to greater than 10 in strain CBA/J (12.1 ± 1.7 fold increase) 
(Fig.  2). Histologic examination of the livers indicated that 
the ALT increases were associated with hepatocellular degen-
eration and necrosis. Inflammatory cells were also found to be 
FIG. 1. Organ-to-body weight ratios (%) are shown for (A) kidney weight and (B) liver weight. Values are expressed as the average ± SEM with white bars 
and black bars, indicating values for vehicle-treated and DB289-treated animals, respectively. *Significant difference between treated and control animals within 
a strain (p < 0.05).
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centered around necrotic hepatocytes in both periportal and 
centrilobular areas (data not shown). In strain C3H/HeJ, these 
findings were accompanied by mild-to-moderate midzonal 
hepatocellular vacuolation.
Assessment of Renal Injury in Mice Using Standard 
Biomarkers
A statistically significant, yet mild, elevation (p < 0.05) in 
serum BUN was observed in 23 (68%) mouse strains (Fig. 3A). 
Similarly, four strains exhibited changes in sCr, with two 
strains exhibiting a minor increase (NOR/LtJ and LG/J) and 
two strains exhibiting a minor decrease (LP/J and WSB/EiJ) 
with DB289 treatment (Fig. 3B). However, the increase in both 
BUN and sCr was minor and all values were well within the 
standard mouse reference range for the analytes.
Assessment of Renal Injury in Mice Using Urinary 
Biomarker, KIM-1
To better characterize the renal response to DB289 in the 
MDP, a sensitive biomarker of regeneration due to proximal 
tubule injury, KIM-1, was measured in urine collected over-
night prior to necropsy. A  marked interstrain variation was 
observed in urinary elimination of KIM-1 with fold increases 
in the DB289-treated animals ranging from 0.03 ± 0.02 
(AKR/J) to 16.7 ± 8.4 (CE/J) (Fig. 4A). Of the strains tested, 
38% demonstrated a significant KIM-1 increase with respect 
to control values. Neither BUN nor sCr values were correlated 
with KIM-1 (p > 0.05). The strains that displayed the most sen-
sitivity to DB289-related kidney responses were C57BLKS/J, 
BTBR T + tf/J, NON/ShiLtJ, A/J, C57BL/6J, C3H/HeJ, and 
CE/J; these strains exhibited a KIM-1 fold change greater 
than five times the average of the vehicle-treated animals. The 
majority of KIM-1 increases were not associated with observ-
able histologic lesions, supporting the increased sensitivity of 
KIM-1 as a biomarker for detecting renal injury over tradi-
tional histologic methods. In addition, there was no correla-
tion between extent of renal injury, as assessed by KIM-1 and 
liver toxicity, as assessed by serum ALT (R2 = 0.003, p = 0.36, 
Fig. 4B).
Identification of Genetic Variation Associated With 
Response to DB289
To determine genetic variants that are associated with kid-
ney responses due to DB289, GWA mapping was performed. 
There were no significant QTL associated with an increase 
in ALT (data not shown). However, several SNPs were asso-
ciated with urinary KIM-1 elimination, and the strength of 
association in some instances far exceeded the correction for 
multiple comparisons (Fig. 5A and Table 1). Of the significant 
SNPs that were associated with a known gene, the majority 
were associated with genes involved in the regulation of lipids 
(Pcsk5, Pip5k1a, Soat2, and Sptlc1; Table 2). Polymorphisms 
in Pde7a, a protein involved in cytokine production in natural 
killer T (NKT) cells, were significantly associated with the kid-
ney response. Interestingly, genes involved in oxidative stress 
and heat/cold shock were also implicated, including Dnajc5b, 
Mtfr1, and Csde1. Regulatory genes that were implicated in 
the response included Nr1h5, Eif2ak3, Eif4b, and Zfp740. The 
majority of the association was driven by genetic variation 
in high responder strains A/J, C3H/HeJ, and CE/J, as well as 
midresponder strain CBA/J (Supplemental table 3).
Ten of the GWA significant genes were associated in a 
genetic network with several genes associated with tissue 
development and cellular proliferation, including a link to the 
gene encoding KIM-1 (Havcr1; Fig. 5B). Genes at the center 
of the network, myelocytomatosis oncogene (Myc) and FBJ 
osteosarcoma oncogene (Fos), are key regulators of cellular 
proliferation.
FIG. 2. Fold changes are shown as the average of DB289-treated animals over the average of vehicle-treated animals within a strain for serum ALT levels 
collected at necropsy ± SEM.
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Kidney Tissue Exposure to DB289
To investigate whether strain-specific differences in the 
kidney response to DB289 were due to differences in kidney 
exposure to the parent or active metabolite (DB75), kidney 
tissue from each mouse was measured (Fig. 6A). Parent drug 
(DB289) was not detected. There was no observed correlation 
between the urinary KIM-1 concentrations for each mouse and 
the concentration of DB75 in the kidney tissue (R2  =  0.002, 
p = 0.65, Fig. 6B).
DISCUSSION
The observation of severe renal injury in the clinic led to 
an abrupt termination of the development program for DB289, 
which was an otherwise promising treatment for HAT. The 
hypothesis tested in this study was that the failure to detect this 
serious liability prior to entering the clinic may have resulted 
from an insufficient genetic diversity in the species utilized for 
standard nonclinical testing.
In each inbred strain studied, levels of the standard serum 
biomarkers of renal injury, BUN, and sCr remained within 
the standard reference ranges following DB289 treatment and 
would not have been considered significant in standard toxicity 
screens. However, DB289 treatment resulted in a marked 
increase in the urinary elimination of the renal proximal 
tubule injury marker KIM-1 among some but not all mouse 
strains. KIM-1 is present in low levels in healthy kidney 
tissue, but is expressed at high levels in regenerating proximal 
tubule epithelial cells following toxic injury (Vinken et  al., 
forthcoming). The histological lesions observed in association 
with DB289 treatment were exclusively located in the proximal 
tubule, further supporting the use of KIM-1 in studies to 
assess degree of toxic response to DB289. That histological 
FIG. 3. Serum levels of (A) BUN and (B) sCr are shown across mouse strains. Gray circles indicate average values for vehicle-treated animals and black 
triangles indicate average values for DB289-treated animals (± SEM). *Significant difference between treated animals within a strain (p < 0.05).
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evidence of proximal tubule injury was not observed in all 
strains with elevations in urinary KIM-1 is consistent with the 
high sensitivity of KIM-1 to detect kidney injury in rodents 
(Vaidya et al., 2010) and in man (Liangos et al., 2009). KIM-1 
therefore enabled detection and quantification of potentially 
injurious responses occurring below the detection capabilities 
of standard approaches. The data presented here indicate that 
an MDP approach to early phase toxicity testing using KIM-1 
would have identified the kidney as a potential target organ 
for toxicity in the clinical trials. Urinary KIM-1 might then 
have been used as a biomarker to detect and monitor for renal 
toxicity in the clinical trials. Importantly, increased levels of 
KIM-1 in genetically sensitive strains enabled the use of GWA 
mapping to identify genetic variants that may contribute to the 
kidney response to DB289.
Most of the genes identified by GWA for KIM-1 levels are 
linked to cellular proliferation via regulatory gene networks 
(Fig.  5). This may not be entirely surprising because KIM-1 
levels should directly reflect the rate of proliferation of the 
renal proximal tubular epithelia. Functional variations in the 
identified genes may therefore affect the kidney’s ability to 
repair after a toxic injury. The predominance of associations 
with cellular proliferation genes may indicate that the major 
factor underlying susceptibility to kidney injury due to DB289 
is variation in the ability to repair after injury. It may be import-
ant that many of the associated genes are involved in lipid 
metabolism. Disruptions in lipid metabolism following acute 
kidney injury in mice can precipitate the onset of progressive 
renal disease and, ultimately, renal failure (Zager et al., 2011). 
It should be noted that the association with genes involved in 
lipid homeostasis may not solely reflect membrane synthesis 
during cell proliferation. It has also been reported that diverse 
forms of acute kidney injury are mediated by “lipotoxic” factors 
that include lipid dysregulation within both mouse and human 
kidney cells (Johnson et al., 2005; Zager et al., 2001, 2005). It 
may therefore be possible that perturbations in these pathways 
FIG. 4. (A) Fold changes are shown as the average (± SEM) of DB289-treated animals over the average of vehicle-treated animals within a strain for urinary 
KIM-1 levels collected 18 h prior to necropsy. δ indicates that the KIM-1 levels were below the quantifiable limit for strains C58/J, SEA/GnJ, and P/J. (B) A cor-
relation plot is shown for ALT measured in the serum on day 11 and KIM-1 accumulation in the urine for 18 h between days 10 and 11. The solid line indicates 
the regression line and dotted lines indicate the 95% confidence interval.
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could lead to increased susceptibility to proximal tubular 
injury. Unfortunately, subsequent in vivo studies to investigate 
the mechanisms of Pcsk5 are not possible using genetic knock-
out animals as the loss of this essential gene causes embryonic 
lethality (Essalmani et al., 2006).
The gene with the greatest degree of association to KIM-1 
levels, as well as the largest number of associated SNPs contained 
within the gene, was proprotein convertase subtilisin/kexin 
type 5 (Pcsk5), a serine protease that cleaves and inactivates 
endothelial and lipoprotein lipases. In addition to PCSK5’s 
involvement in cell proliferation networks (Fig.  5), PCSK5-
regulated lipases influence circulating levels of high-density 
lipoprotein, low-density lipoprotein (LDL), and chylomicrons 
(Jin et al., 2005). Overexpression of PCSK9 protein, which is 
regulated by PCSK5 (Seidah et al., 2008; Zaid et al., 2008), in 
mice results in a marked decrease in circulating LDL coincident 
with a decrease in hepatic LDL receptors (Lalanne et al., 2005; 
Maxwell and Breslow, 2004). PCSK5 is expressed in the kidney 
and may help regulate kidney concentrations of cholesterol 
and other lipids (Essalmani et  al., 2008). It may be relevant 
that following acute sublethal injury in the kidney, the kidney 
has been shown to be protected from subsequent toxic insult; 
furthermore, this property may be unique to proximal tubule 
cells due to increased cholesterol content that occurs subsequent 
to the initial injury (Zager et al., 2001). It should be noted that 
another gene involved in cholesterol absorption and secretion, 
sterol O-acyltransferase 2 (Soat2), was associated with urinary 
KIM-1 elimination. To date, there has been no direct connection 
reported between Soat2 expression and kidney injury. However, 
inhibition of SOAT2 has been shown to have significant 
impact on hypercholesteremia and atherosclerosis owing to 
its functional role in the esterification of cholesterol with its 
substrate, fatty acyl coenzyme A, to facilitate both intracellular 
storage and intercellular transport (An et al., 2006). Therefore, 
as with Pcsk5, functional variation in Soat2 may contribute to 
injury susceptibility by influencing kidney content of lipids.
FIG. 5. (A) GWA mapping of DB289-induced elevations in KIM-1. The 
fold change increase in urinary KIM-1 was used to identify genomic intervals 
significantly associated with the renal response. Dots above the 5% false dis-
covery rate (FDR) threshold (red line) indicate a significant −log P association 
score at the indicated SNP. Marker colors indicate the chromosome number 
within the mouse genome. Labels denote genes that include significant SNPs. 
# indicates that significant SNPs are within intergenic regions and not associ-
ated with a specific gene. (B) The network map of GWA significant genes is 
shown. Nodes highlighted in orange represent significant QTL. The gene for 
KIM-1 (Havcr1) is highlighted in green color. Solid arrows between nodes 
indicate a direct effect, dashed arrows indicate an indirect effect, and solid lines 
indicate direct binding.
TABLE 1











SNP function  
class
9.20 19 17850776 Pcsk5 Intron
7.60 19 17659581 Pcsk5 Intron
6.77 19 17586468 Pcsk5 Intron
6.77 19 17643240 Pcsk5 Intron
6.77 19 17748435 Pcsk5 Intron
6.77 19 17882060 Pcsk5 Intron
7.50  3 102860565 Csde1 Intron
7.50  3 102753254 Nr1h5 Exon (coding 
nonsynonymous)
6.84  3 19168471 Pde7a Intron
6.84  3 19198078 Pde7a Intron
6.84  3 19425662 Dnajc5b Intron
6.81 17 79266139 Eif2ak2 Intron
6.84 15 101906580 Eif4b Intron
6.84 15 101912637 Eif4b Intron
6.84  3 19101103 Mtfr1 Intron
6.84  3 94876525 Pip5k1a Intron
6.84 15 101981667 Soat2 Intron
6.84 13 53468361 Sptlc1 Intron
6.84 15 102043864 Zfp740 3′ untranslated 
region
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TABLE 2
Genes Associated With Genetic Differences in KIM-R1 Response and Reported Functions
Gene symbol Gene name Function
Pcsk5 Proprotein convertase subtilisin/kexin type 5 Critical role in cholesterol metabolism by controlling levels of 
circulating LDL
Csde1 Cold shock domain containing E1, RNA binding Unknown
Nr1h5 Nuclear receptor subfamily 1, group H, member 5 DNA binding, receptor activity, metal ion binding
Pde7a Phosphodiesterase 7A Cellular proliferation and cytokine production in NKT cells
Dnajc5b DnaJ (Hsp40) homolog, subfamily C, member 5 beta Heat shock protein binding
Eif2ak2 Eukaryotic translation initiation factor 2-alpha kinase 2 Serine/threonine protein kinase that phosphorylates translation initiation 
factor EIF2S1, inhibiting protein synthesis
Eif4b Eukaryotic translation initiation factor 4B mRNA helicase
Mtfr1 Mitochondrial fission regulator 1 Mitochondrial protein that protects cells from oxidative stress
Pip5k1a Phosphatidylinositol-4-phosphate 5-kinase, type I, alpha Phospholipid biosynthesis
Soat2 Sterol O-acyltransferase 2 Produces cholesterol esters from long-chain fatty acyl CoA and 
cholesterol; cholesterol absorption and secretion of very LDLs
Sptlc1 Serine palmitoyltransferase, long chain base subunit 1 Key enzyme in sphingolipid biosynthesis
Zfp740 Zinc finger protein 740 Transcription factor
FIG. 6. (A) The concentration of DB75 in kidney tissue at time of necropsy is shown (average ± SEM) with strains ordered as in Figure 4A (increasing KIM-1 
fold changes). (B) A correlation plot is shown for DB75 concentration in the kidney tissue and KIM-1 accumulation in the urine on day 10–11. The solid line 
indicates the regression line and dotted lines indicate the 95% confidence interval.
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One additional possibility is that DB289 or its metabolites 
are trafficked in blood or in tissues by lipid carriers and that 
variation in Pcsk5 and/or Soat2 may thereby influence proxi-
mal tubule exposure to DB289. However, concentration of 
DB75, the active metabolite, in the kidney across mouse strains 
was not correlated with KIM-1 levels, suggesting that this may 
be an unlikely basis for the association observed.
Pde7a (phosphodiesterase 7A), a gene not linked to the cell 
proliferation network, was identified as a gene that may also 
play a role in the response to DB289-mediated renal injury. 
The function of the PDE7A protein is to regulate cytokine 
production in NKT cells. NKT cells have been shown to play an 
essential role in the innate immune response of renal ischemia-
reperfusion injury by mediating production of interferon-γ, 
which propagates the injury (Li et al., 2007). It was demonstrated 
that the absence of NKT cells in CD1d(−/−) or Jα18(−/−) 
genetic knockout mice accentuated the severity of renal injury 
following ischemia-reperfusion injury, indicating that NKT 
cells are protective (Yang et al., 2011). It is therefore possible 
that NKT cells or cytokine signaling cascades may modulate the 
extent of renal injury during treatment with DB289.
Proximal tubule cell toxicity may also be potentiated by vari-
ation in mitochondrial fission regulator 1 (Mtfr1), a gene that is 
involved in antioxidant activity (Monticone et al., 2010). Loss 
of function of this gene has been shown to cause reactive oxy-
gen species-mediated DNA damage in the mouse, particularly 
in the testes where expression is the greatest (Monticone et al., 
2007). The specific role that this protein may play in the kidney 
response to DB289 requires further study.
In summary, our approach with the MDP detected the renal 
injury potential of DB289 where traditional nonclinical testing 
failed, and identified urinary KIM-1 as a biomarker that could 
potentially be translated to the clinic to detect this target organ 
toxicity at an early stage. Variation in susceptibility to renal 
injury as assessed by KIM-1 was associated with sequence 
variation in genes related to cell proliferation, lipid biosynthe-
sis and transport, oxidative stress, and cytokine signaling. The 
implicated genes may control the rate of cell proliferation in 
response to tubular injury, but may also have a role in suscep-
tibility to initial injury and progression. Unfortunately, DNA 
samples from clinical DB289 studies were not available to test 
the hypotheses generated by the mouse models in humans. 
Further studies with human primary cells and in animal mod-
els are necessary to elucidate the mechanisms by which these 
gene variants may modulate the renal outcome. Finally, the 
MDP mouse strains identified as susceptible to DB289 kid-
ney toxicity should be useful to test renal toxicity potential for 
next-in-class diamidine analogs now in development.
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